Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Creatine Safety, Tolerability, & Efficacy in Huntington`s Disease (CREST-E)


Creatine Safety, Tolerability, & Efficacy in Huntington`s Disease (CREST-E)




Huntington`s disease (HD) is a slowly progressive disorder that devastates the lives of those affected and their families. There are no treatments that slow the progression of HD, only mildly effective symptomatic therapies are available.Creatine monohydrate is considered a nutritional supplement. The purpose of CREST-E is to test whether high-dose creatine can slow the progressive functional decline that occurs in persons 18 years or older with early clinical features of HD. The long-term safety, tolerability and effectiveness of up to 40 grams daily creatine compared to placebo is studied. A variety of biological processes are assessed for markers of disease activity or progression and creatine effects. Up to 50 active research centers globally will enroll 650 subjects.

Study Status: Recruiting

Jennifer Mule 216-444-1134

Condition Intervention Phase
Huntington`s Disease Drug: Creatine Monohydrate
Drug: Placebo
Phase 3

Verified by Massachusetts General Hospital July, 2013

Sponsored by: Massachusetts General Hospital
Information provided by: Massachusetts General Hospital identifier: NCT00712426

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio 44195
United States

Steven M Hersch, MD, PhD., Principal Investigator
Giovanni Schifitto, MD., Principal Investigator
Diana Rosas, MD, MS., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site